M Kita

Tokyo Women's Medical University, Edo, Tōkyō, Japan

Are you M Kita?

Claim your profile

Publications (40)33.34 Total impact

  • International journal of radiation oncology, biology, physics 05/2013; 86(1):4-5. · 4.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate and compare the efficacy of medium-dose-rate (MDR) and low-dose-rate (LDR) intracavitary brachytherapy (ICBT) for uterine cervical cancer. We evaluated 419 patients with squamous cell carcinoma of the cervix who were treated by radical radiotherapy with curative intent at Tokyo Women's Medical University from 1969 to 1999. LDR was used from 1969 to 1986, and MDR has been used since July 1987. When compared with LDR, fraction dose was decreased and fraction size was increased (1 or 2 fractions) for MDR to make the total dose of MDR equal to that of LDR. In general, the patients received a total dose of 60 to 70 Gy at Point A with external beam radiotherapy combined with brachytherapy according to the International Federation of Gynecology and Obstetrics stage. In the LDR group, 32 patients had Stage I disease, 81 had Stage II, 182 had Stage III, and 29 had Stage IVA; in the MDR group, 9 patients had Stage I disease, 19 had Stage II, 55 had Stage III, and 12 had Stage IVA. The 5-year overall survival rates for Stages I, II, III, and IVA in the LDR group were 78%, 72%, 55%, and 34%, respectively. In the MDR group, the 5-year overall survival rates were 100%, 68%, 52%, and 42%, respectively. No significant statistical differences were seen between the two groups. The actuarial rates of late complications Grade 2 or greater at 5 years for the rectum, bladder, and small intestine in the LDR group were 11.1%, 5.8%, and 2.0%, respectively. The rates for the MDR group were 11.7%, 4.2%, and 2.6%, respectively, all of which were without statistical differences. These data suggest that MDR ICBT is effective, useful, and equally as good as LDR ICBT in daytime (about 5 hours) treatments of patients with cervical cancer.
    International journal of radiation oncology, biology, physics 01/2012; 84(1):137-45. · 4.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the impact of dysadherin and E-cadherin expression on the clinical outcomes, including the treatment outcomes and recurrence pattern, in patients with head and neck cancer. Tumor specimens were obtained from 48 head and neck cancer patients who were treated by radiation therapy and the specimens were immunohistochemically stained for dysadherin and E-cadherin. The expressions were graded according to the percentage area occupied by cancer cells showing positive staining for E-cadherin and dysadherin as follows: grade 0, less than 10%; grade 1, 10-50%; grade 2, more than 50%. The correlations between the expression of E-cadherin and dysadherin and the clinical outcomes, including the treatment outcomes and recurrence pattern, were analyzed. The complete response (CR) rate in the patients with a dysadherin expression grade of 0 or 1 was 70% and that in the patients with dysadherin expression grade of 2 was 38%; the difference was significant (p < 0.05). Regarding the pattern of recurrence, the expression grade of dysadherin or E-cadherin alone was not correlated with the recurrence pattern; however, patients with a difference in the expression grade between dysadherin and E-cadherin (Dys-Ecad value) of 1 or 2 showed a significantly higher rate of lymph node and/or distant metastasis (55%) as compared with those with a Dys-Ecad value of < 1 (22%) (p < 0.05). Dysadherin and E-cadherin expression might serve as useful prognostic factors in patients with head and neck cancer treated by definitive radiation therapy.
    Anticancer research 01/2008; 28(6B):3859-64. · 1.87 Impact Factor
  • Yuko Kaneyasu, Midori Kita
    Nippon rinsho. Japanese journal of clinical medicine 11/2004; 62 Suppl 10:386-90.
  • Nippon rinsho. Japanese journal of clinical medicine 05/2000; 58 Suppl:173-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: We analyzed 58 cases of advanced or recurrent cervical cancer treated with intra-arterial infusion chemotherapy (IAIC) with or without radiotherapy. Two separate IAIC regimens were administered since 1985: group I consisted of 5-FU + MMC +/- ADR (30 patients) and group II consisted of CDDP + MMC +/- 5-FU (28 patients). The tip of a catheter was placed in the bifurcation of the abdominal aorta (1 way method: 45 patients regimen II: 15) between 1977-1984. We have used selective catheterization (2 ways method: 9) since 1995 in order to get good drug distribution. However we experienced grade 4 toxic effect of cutaneous and pain with this method, so we have used a 3 ways method (4 patients) since 1998. The two-year survival rete was 60% with the 1 way method, and 67% with the 2 ways method and regimen II. Severe adverse effects (grade 3 + 4) were found in 53, 56, 0%, respectively, by each of the three methods (1, 2, 3 ways) hematologically, 13, 22, 0% in gastrointestinally, 0, 44, 0% in cutaneously and 0, 56, 0% in pain or neurotoxicity. These data suggest that IAIC by the 3 ways method is a useful treatment for advanced or recurrent cervical cancer. However, one should check the blood flow distribution periodically, and control concentration of drugs.
    Gan to kagaku ryoho. Cancer & chemotherapy 11/1999; 26(12):1860-3.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The results of definitive radiotherapy for superficial esophageal cancer is presented. Twenty-one patients with superficial squamous cell carcinoma of the esophagus were treated by definitive radiotherapy with megavoltage x-rays in Tokyo Women's Medical College from 1975 to December 1990. Eight patients refused surgery and 13 patients were considered to be unsuitable for surgery due to advanced age or morbid conditions such as severe pulmonary dysfunction, myocardial infarction, liver cirrhosis, and other cancer. Radiotherapy was performed using 1.8-2.2 Gy fraction dose, 5 times a week and with a total dose of 50-76 Gy/5-7 weeks (median; 70 Gy). Three patients received intraluminal radiotherapy in addition. Combined chemotherapy was performed in four cases, and three cases received it before radiotherapy and one case after radiotherapy. Overall survival rate was 40.8%, and the cause-specific 5-year survival rate was 61.7%. The 5-year survival rate of the group with morbid conditions was 17.5%, but that of the group without morbid conditions was 60.6%. Seven patients developed recurrence (primary site: 3, lymph nodes: 3, lung: 1) and one patient revealed multicentric cancer of the hypopharynx with wide submucosal spread of the esophagus at 28 months after radiotherapy. No patient developed severe side effect due to radiotherapy. Definitive radiotherapy with or without chemotherapy can be applied as an alternative therapy to surgery for superficial esophageal cancer, even for the operable patients under good general condition.
    International Journal of Radiation OncologyBiologyPhysics 12/1994; 30(4):959-64. · 4.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: As predictors of tumor response by radiotherapy, tumor with or without c-myc amplification and DNA histogram pattern were analyzed and evaluated for patients' prognosis. There was no relation between c-myc amplification and DNA ploidy pattern in this study. These factors also showed no relation to response rate and survival. But all of the tumors with c-myc amplification and aneuploid pattern exhibited a complete response by radiotherapy. The tumors with c-myc amplification and aneuploid pattern may be more radiosensitive than without amplification and diploid. These data suggested that c-myc amplification and ploidy pattern might be a predictive parameter before radiotherapy.
    Gan to kagaku ryoho. Cancer & chemotherapy 05/1993; 20(6):834-8.
  • International Journal of Radiation Oncology Biology Physics - INT J RADIAT ONCOL BIOL PHYS. 01/1992; 24:246-246.
  • T Okawa, M Kita, M Tanaka
    [Show abstract] [Hide abstract]
    ABSTRACT: At present, surgery and radiotherapy have been employed successfully to manage carcinoma of the cervix. Generally, the choice of treatment is determined primarily by the stage of the disease. Radiotherapy for cervical cancer must be consist ed of external radiotherapy and brachytherapy. Brachytherapy is a significant and important part of the overall management of the patients with cervical cancer. The selection of a given therapeutic modality depends on the general condition of the patients, gross characteristics of the tumor and availability of expertise to offer adequate radiation therapy.
    Gan no rinsho. Japan journal of cancer clinics 09/1990; 36(10):1137-42.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Considering the relationship between tumor lethal dose and normal tissue tolerance: the therapeutic ratio, radiation oncologists have been performed the radiotherapy for cancer patient. The basic principle of radiotherapy is to have a good result (curability), to be tolerable in side effects and to have a comfortable life after radiation. Radiotherapy is the important strategy for an early stage of cancer with conserving the function and structure, and for an advanced or a recurrent stage of cancer with contributing to improve the quality of life. Recently, advantage of radiation tools and supportive care of cancer treatment, have been able to decrease the incidence of late injuries and complications. Radiotherapy must be planned on basis of considering therapeutic ratio and should be performed with optimum radiation in the multimodal treatment for cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy 05/1990; 17(4 Pt 2):895-9.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical efficacy of LC9018, a biological response modifier prepared from heat-killed Lactobacillus casei YTT9018, used in combination with radiation was studied in a randomized controlled trial on 61 patients with carcinoma of the uterine cervix of Stage IIB or III. The combination therapy with LC9018 demonstrated a significant effect on tumor reduction, compared with radiation therapy alone, at the cumulative doses of 15-Gy and 30-Gy external irradiation (P less than 0.05). Histologic study confirmed that LC9018 also enhanced the therapeutic effect of the irradiation. Moreover, LC9018 seemed to be useful in protecting the patients from leukopenia during radiotherapy. This study suggests that LC9018, when used in combination with radiotherapy, will be an effective adjuvant immunotherapeutic agent. More studies in a large series of patients will, however, be needed to establish its long-term efficacy, safety, and effects on both prognosis and enhancing radiotherapy.
    Cancer 12/1989; 64(9):1769-76. · 4.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prospective randomized clinical study was conducted to evaluate the factor of radiation field in radiotherapy for malignant glioma from 1981 to 1988 at Tokyo Women's Medical College. Radiation methods were randomized to two groups; (I) whole brain (40 Gy) and local irradiation (18 Gy), total dose 58 Gy/29 f/6 weeks (TDF 91), (II) local irradiation, total 56 Gy/28 f/6 weeks (TDF 90). Twenty three cases were registered as group I and 26 cases as group II. Two and four years cumulative survival rate were 43% and 17% in group I and 39% and 27% in group II. There were no significant differences on response, survival, recurrent pattern, late effect and complications between whole brain and local irradiation. This study confirmed that local control was the most important in the treatment of malignant glioma.
    Gan no rinsho. Japan journal of cancer clinics 10/1989; 35(11):1289-94.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Three hundred and eleven patients with locally advanced esophageal cancer were treated by radiation therapy from 1968 to 1983 at Tokyo Women's Medical College. Of these, 288 patients with previously untreated, histologically confirmed squamous cell carcinoma but previously treated with curative intent, were eligible for analysis. The cumulative 5-year survival rate of 288 patients given radical radiotherapy was 9.0%. Sex, tumor length, and Stage (AJC) had a great influence on prognosis. The five-year survival rate in males was 5.4% and in females was 22.4%. The five-year survival rate in cases with a tumor length of 5 cm or less was 17.7% in 5-10 cm was 10.0%, and in 10 cm or above was 2.8% and they were 20.2% for Stage I, 9.9% for Stage II, and 2.6% for Stage III. There were no significant differences of survival rate among age, tumor site, and tumor type on X ray film. This data suggests that comparatively early, small-volume tumors share a significant potential for cure by radiotherapy, but potent combined therapy is necessary for the treatment of advanced cancers.
    International Journal of Radiation OncologyBiologyPhysics 08/1989; 17(1):49-54. · 4.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Seventy-six cases with squamous cell carcinoma of the maxillary sinus were treated with radiotherapy and surgery with or without intra arterial infusion between 1969 to 1985 at the Tokyo Women's Medical College. T classification was made of all cases using the Japan Joint Committee (JJC, 1967), American Joint Committee (AJC, 1977) and Union Internationale Contre le Cancer (UICC, 1987) classifications. 1) By the JJC classification, there were 20 cases in T2, 44 in T3 and 12 in T4. By the AJC classification, there were 9 cases in T2, 58 in T3 and 9 in T4. The classification of 14 cases were changed from JJC T2 to AJC T3, because of extension to the medial nasal meatus. By the UICC classification, there were 27 T2 cases, 32 T3 and 17 T4. 2) Cervical lymph node metastasis was detected in 14 cases (18%) at initial diagnosis and most were found in T3 and T4 cases. 3) The cumulative 5-year survival rates were 67% for T2, 32% for T3 and 25% for T4 by the JJC classification and statistical differences (p less than 0.05) were seen in T2-T3 and T2-T4. In the AJC classification, these were 71% for T2, 37% for T3 and 22% for T4 and no statistical significance was found among them. By the UICC classification, the 5-year survival was 58% for T2, 26% for T3 and 38% for T4 and marked statistical significance (p less than 0.01) was seen in T2-T3 and T2-T4. 4) The cumulative 5-year survival rate in 14 patients with tumor extension to the medial nasal meatus was 55% and it is appropriate to define this stage as T2 in the new UICC classification. These data suggested that UICC classification (1987) is useful and correlated with prognostic analysis.
    Nippon Gan Chiryo Gakkai shi 07/1989; 24(6):1277-87.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Eighty four patients with recurrent colorectal cancer were treated by radiotherapy at Tokyo Women's Medical College from January 1969 to September 1987. 1) Sixty four cases (76% of all) recurred within 2 years after initial surgery. 2) the most common initial recurrent site was primary lesion alone (58%) and followed by primary lesion and distant metastasis (18%), lymph node metastasis (13%) and others (11%). 3) Over all response rate (CR + PR) was 57% (20/35). There was no relationship between response rate and total dose. By treatment procedure, response rate was 50% (12/24) in radiotherapy alone, 50% (1/2) in surgery and radiotherapy, and 70% (7/10) in radiotherapy and intra-arterial infusion. 4) Pain relief was obtained 92% of cases. 5) After initial recurrences, 50% of survival time was 12 months and 5 year cumulative survival rate was 7%. In the cases of responders (CR + PR), 5 years survival rate was 11% and there were no 3 years survivors in the cases of non responders (MR + NC). 6) There were no serious acute reaction and late complications. These data suggested that radiotherapy for recurrent colorectal cancer were effective and useful.
    Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica 06/1989; 49(5):607-13.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This report analyzed the 7,763 cases treated at T.W.M.C., where radiotherapy has been mainly used, between 1968 and 1984. Of these, 258 cases (3.3%) had multiple primary malignant neoplasms, among which 88 cases involved head and neck cancer. The incidence averaged 1.6% during the first 5 years, but increased to an average of 5.7% during the last 5 years. Among head and neck cancer the incidence of multiple primary malignant neoplasms was 8.5% (88/1,033) and the incidence has been gradually increasing annually. Cancers of the head and neck were frequently combined with another primary lesion in the head and neck area or in the digestive tract, especially esophagus and stomach, followed by one in the both cases. The great majority of cancers in the head and neck occurred as the first cancer at age 60-70. The head and neck region is where the respiratory system and digestive system, including lymphatic organs originate and where the external carcinogenic factors enter into the body. These data suggested that multiple primary malignant neoplasms have been increasing in number and becoming an increasing problem. The possibility of multiple primary malignant neoplasms should not be forgotten in routine cancer related clinical work.
    Nippon Gan Chiryo Gakkai shi 06/1989; 24(5):957-65.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Twenty-one patients of laryngeal cancer (T2, T3) were treated with Twice-A-Day fractionation radiotherapy (TADF) between April, 1986 and December, 1987. Tumor control and mucosal reaction were evaluated to compare with effects between TADF and Conventional fractionation radiotherapy (CF). Methods of TADF were 1.2-1.5 Gy per fraction, two fractions per day with a minimum interval of 6 Hr., 5 days a week and 66-72 Gy for total dose. In CF, they were 1.8-2.0 Gy per fraction, one fraction per day, 5 days a week and 60-70 Gy for total dose. Complete response dose were 57 Gy in average for TADF and 47 Gy for CF. There was no significant difference. Early mucosal reaction was observed slightly severe in TADF than in CF. But, there was no significant difference among them. Split time was neened 10 days in average for TADF and 7 days for CF. There was no elongation of overall time in TADF. Follow-up time was too short to discuss about late reaction. But there were no serious complications among the patients with 2 years follow-up. These data suggested that radiotherapy of TADF was effective and should be clinically studied furthermore.
    Gan no rinsho. Japan journal of cancer clinics 11/1988; 34(13):1768-72.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A prospective randomized clinical trial comparing small, large and twice-a-day fraction for the relief of painful bone metastases was performed from 1981 to 1986 at Tokyo Women's Medical College Hospital. Eighty patients with painful bone metastases (92 sites) were divided into three radiation methods which were conventional fraction scheme of 5 times/week at 2 Gy/day for a total of 30 Gy/15 fractions (Group I, TDF: 49), 2 times/week at 4.5 Gy/day for a total of 22.5 Gy/5 fractions (Group II, TDF: 50) and 3 times/week at 2 Gy/day twice a day at a minimum interval of 6 h for a total of 20 Gy/10 fractions (Group III). Pain was assessed using a score and response rate was 76% in Group I, 75% in Group II and 78% in Group III which were not statistically significant mutually. Group II and III regimes were found to have an earlier shorter onset of pain relief than Group I, but the dose of onset of pain relief was almost the same. Our data suggested that individualization of radiotherapy schedules based on to assess the patient's condition and the expected quality of life and to consider radiation site and size of field, was more important than the fractionation regime in the treatment of painful bone metastases.
    Radiotherapy and Oncology 11/1988; 13(2):99-104. · 4.86 Impact Factor
  • T Okawa, M Kita
    [Show abstract] [Hide abstract]
    ABSTRACT: Intra-arterial infusion chemotherapy has become widely accepted in the multimodal treatment of many malignant tumors. We have used Port-A-Cath, which is an implantable drug delivery system, for regional infusion therapy in cancer chemotherapy since April 1984 and made a study protocol for evaluation of safety, usefulness and reliability. Twenty-two patients with pancreatic and intra-pelvic tumors have been treated with this method. Drugs of this series were adriamycin and mitomycin-C, using intermittently and 5-Fluorouracil continuously with or without radiotherapy. In localized unresectable adenocarcinoma of pancreas, the median implanted days of Port-A-Cath was 139 days and the median survival from implantation was 212 days. On the other hand, in advanced or recurrent intra-pelvic tumors, the median implanted day was 274 days and median survival time from implantation was 583 days. One case developed skin necrosis at the implanted area, and three had infections which were able to be managed. The findings suggest that Port-A-Cath assures safety and good quality of life in cancer patients because of the freedom of movement, normal physical appearance and barriers to infection due to subcutaneous placement.
    Gan to kagaku ryoho. Cancer & chemotherapy 09/1988; 15(8 Pt 2):2659-63.

Publication Stats

212 Citations
33.34 Total Impact Points


  • 2000–2013
    • Tokyo Women's Medical University
      • Department of Radiation Oncology
      Edo, Tōkyō, Japan
  • 2004–2012
    • Hiroshima University
      • • Department of Radiation Oncology
      • • Department of Radiology
      Hiroshima-shi, Hiroshima-ken, Japan
  • 1989
    • Tokyo Junshin Women's College
      Edo, Tōkyō, Japan